Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00328497 · ClinicalTrials.gov registry record · Phase 2

A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors

A Phase 2 study of Carcinoid Tumor, sponsored by CASI pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
31
Enrollment target
1
Study location

NCT00328497: Completed Phase 2 study of Carcinoid Tumor, sponsored by CASI pharmaceuticals.

NCT00328497 is a Phase 2 study of Carcinoid Tumor that has completed, run by CASI pharmaceuticals. The registered enrollment target is 31 participants, below the 95-participant average among 8 other Carcinoid Tumor trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00328497, a Phase 2 study of Carcinoid Tumor, has completed, sponsored by CASI pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
31 participants
Enrollment target
1
Study location

Study Summary

This single center, open-label study will evaluate the safety and efficacy of Panzem (2-methoxyestradiol, 2ME2) Nanocrystal Dispersion (NCD) administered orally with recombinant human monoclonal antibody against vascular endothelial growth factor (bevacizumab) administered intravenously, in patients with locally advanced or metastatic carcinoid tumors.

Conditions Studied

Carcinoid Tumor

Interventions

  • DRUG Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)

Study Locations (1)

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2006-05
Est. Completion 2009-12
Phase Phase 2
CASI pharmaceuticals

11 total trials

What the finished NCT00328497 record still lists

NCT00328497 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 95-participant average among 8 other Carcinoid Tumor trials with a reported enrollment target (67% lower).

The record links to 1 condition, with Carcinoid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab) is the first listed.

NCT00328497 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00328497 about?

NCT00328497 is a clinical study titled "A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors". This single center, open-label study will evaluate the safety and efficacy of Panzem (2-methoxyestradiol, 2ME2) Nanocrystal Dispersion (NCD) administered orally with recombinant human monoclonal antibody against vascular endothelial growth factor (bevacizumab) administered intravenously, in patients...

What is the current status of trial NCT00328497?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2006-05. Estimated completion is 2009-12.

What conditions does trial NCT00328497 study?

This clinical trial studies the following conditions: Carcinoid Tumor.

What interventions are being tested in trial NCT00328497?

The interventions under investigation include: Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab) (DRUG).

Who is sponsoring clinical trial NCT00328497?

This trial is sponsored by CASI pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00328497 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00328497's enrollment target sits among peer trials

31 7th of 8 higher than 2 of 8 other Carcinoid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Carcinoid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02932618 · 31 participants · Phase 3

    A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

  • NCT03482297 · 31 participants · Phase 1

    Automated Abdominal Binder for Orthostatic Hypotension

  • NCT04016389 · 31 participants · NA

    FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

  • NCT04211675 · 31 participants · Phase 1

    NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00328497, the US trial registry maintained by the National Library of Medicine. NCT00328497 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.